Asembia AXS26 Summit | Biologics by McKesson

Join Biologics at Asembia’s AXS26 Summit

April 26-30, 2026 | Booth #1223

Biologics by McKesson specialty pharmacy is proud to join industry leaders at Asembia’s AXS26 Summit, taking place April 26-30, 2026, at the Wynn & Encore in Las Vegas. As one of the premier gatherings for the specialty pharmacy and biopharmaceutical community, AXS26 brings together thousands of senior decision‑makers shaping the future of patient access, commercialization and therapy delivery.

Visit the McKesson booth #1223 to connect with the Biologics team and explore how our specialty pharmacy supports efficient, patient‑centered commercialization across oncology, rare and orphan diseases, and cell & gene therapies. Whether you’re advancing a new therapy or optimizing an established program, our integrated approach helps streamline access and improve the patient and provider experience.

As a Platinum Sponsor, McKesson is proud to support one of the industry’s most influential specialty pharmacy events.

We look forward to engaging with our biopharma partners at one of the industry’s most influential B2B events.

Resources You Can Use

Oncology Commercialization Support for Biopharma

Rare Disease Solutions for Biopharma

Collaboration in Rare Disease Care

Risk-Based Care for Biopharma

Hear From Our Experts at Asembia

Meeting the Moment: Collaboration and Innovation in an Evolving Healthcare Ecosystem
Tuesday, April 28, 2026 at 1 p.m. PT

As the healthcare ecosystem navigates mounting challenges – from reimbursement pressures to policy shifts to operational challenges – specialty distributors have emerged as strategic partners in the journey to provide the best patient care. This panel will feature real-world perspectives from stakeholders across the industry who have partnered with specialty distributors to navigate change and drive impact. Join us to discover how specialty distribution is fostering innovation, enabling resilience, and unlocking new opportunities to help industry stakeholders meet the future head-on.

Natalie Bedford, SVP, Brand Sourcing & Manufacturer Relations, McKesson
Brian McCartney, VP, Strategic Innovation & Policy, McKesson
Steven Madreperla, President & CEO, Prism Vision Group
Natalie Morris, Director, Public Policy & Reimbursement, Takeda
Ray Tancredi, EVP – Trade Relations, Asembia

Breaking Through Reimbursement Complexities to Enable Patient Access
Wednesday, April 29, 2026 at 1 p.m. PT

Cell and gene therapies (CGTs) are redefining what’s possible in medicine, offering the potential for durable, even curative, outcomes. Yet access to these therapies remains limited—not because of science, but because of the inherent complexities associated with reimbursing these expensive products. Moderated by Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, this panel will bring together payer, provider, and employer perspectives to explore innovative payment and delivery solutions. Panelists will move beyond describing challenges to charting a path forward, examining opportunities to reduce uncertainty, mitigate financial risk, and create sustainable reimbursement approaches.

Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson
Michael A. Evans, Chief Pharmacy Officer, Geisinger
Navneet Majhail, Physician-in-Chief of Blood Cancers, HCA Healthcare Sarah Cannon Cancer Network
Will Shrank, Co-founder and CEO, Aradigm Health